FoleyR.N., ParfreyP.S., SarnakM.J.The clinical epidemiology of cardiovascular disease in chronic renal disease.Am J Kidney Dis1998; 32(Suppl 3): S112–19.
2.
FytiliC.I., ProgiaE.G., PanagoutsosS.A., ThodisE.D., PassadakisP.S., SombolosK.I.Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients.Ren Fail2002; 24: 623–30.
3.
QuaschningT., KraneV., MetzgerT., WannerC.Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease.Am J Kidney Dis2001; 38(4 Suppl 1): S14–19.
4.
IsekiK., YamazatoM., TozawaM., TakishitaS.Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients.Kidney Int2002; 61: 1887–93.
5.
CoreshJ., LongeneckerJ.C., MillerER3rd, YoungH.J., KlagM.J.Epidemiology of cardiovascular risk factors in chronic renal disease.J Am Soc Nephrol1998; 9(12 Suppl): S24–30.
6.
LowrieE.G., LewN.L.Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities.Am J Kidney Dis1990; 15: 458–82.
7.
HabibA.N., BairdB.C., LeypoldtJ.K., CheungA.K., Goldfarb-RumyantzevA.S.The association of lipid levels with mortality in patients on chronic peritoneal dialysis.Nephrol Dial Transplant2006; 21: 2881–92.
8.
LiuY., CoreshJ., EustaceJ.A., LongeneckerJ.C., JaarB., FinkN.E.Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition.JAMA2004; 291: 451–9.
9.
GreenbergJ.A.Hypothesis—The J-shaped follow-up relation between mortality risk and disease risk-factor is due to statistical confounding.Med Hypotheses2002; 59: 568–76.
10.
BuemiM., FloccariF., NostroL., CampoS., CaccamoC., SturialeA.Statins in the prevention of cardiovascular events in patients with renal failure.Cardiovasc Hematol Disord Drug Targets2007; 7: 7–13.
11.
GrundyS.M., CleemanJ.I., MerzC.N., BrewerH.B.Jr., ClarkL.T., HunninghakeD.B.Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.Circulation2004; 110: 227–39.
12.
StrippoliG.F., NavaneethanS.D., JohnsonD.W., PerkovicV., PellegriniF., NicolucciA.Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials.BMJ2008; 336: 645–51.
13.
HarperC.R., JacobsonT.A.Managing dyslipidemia in chronic kidney disease.J Am Coll Cardiol2008; 51: 2375–84.
14.
LinsR.L., MatthysK.E., BilliouwJ.M., DratwaM., DupontP., LameireN.H.Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study.Clin Nephrol2004; 62: 287–94.
15.
RobsonR., CollinsJ., JohnsonR., KitchingR., SearleM., WalkerR.Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. The Perfect Study Collaborative Group.J Nephrol1997; 10: 33–40.
16.
WannerC., KraneV., MarzW., OlschewskiM., MannJ.F., RufG.Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.N Engl J Med2005; 353: 238–48.
17.
WannerC., KraneV., MarzW., OlschewskiM., AsmusH.G., KramerW.Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics.Kidney Blood Press Res2004; 27: 259–66.
18.
XueJ.L., ChenS.C., EbbenJ.P., ConstantiniE.G., EversonS.E., FrazierE.T.Peritoneal and hemodialysis: I. Differences in patient characteristics at initiation.Kidney Int2002; 61: 734–40.
19.
KronenbergF., LingenhelA., NeyerU., LhottaK., KonigP., AuingerM.Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients.Kidney Int Suppl2003; 84: S113–16.
20.
Goldfarb-RumyantzevA.S., HabibA.N., BairdB.C., BarenbaumL.L., CheungA.K.The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis.Am J Kidney Dis2007; 50: 791–802.
21.
SeligerS.L., WeissN.S., GillenD.L., KestenbaumB., BallA., SherrardD.J.HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients.Kidney Int2002; 61: 297–304.
22.
FellstromB.C., HoldaasH., JardineA.G.Why do we need a statin trial in hemodialysis patients?Kidney Int Suppl2003; 84: S204–6.
23.
BaigentC., LandryM.Study of Heart and Renal Protection (SHARP).Kidney Int Suppl2003; 84: S207–10.
24.
IkeeR., HamasakiY., OkaM., MaesatoK., ManoT., MoriyaH.High-density lipoprotein cholesterol and left ventricular mass index in peritoneal dialysis.Perit Dial Int2008; 28: 611–16.
